Omalizumab can inhibit respiratory reaction during aspirin desensitization
Annals of Allergy, Asthma, and Immunology May 24, 2018
Lang DM, et al. - In this randomized, double-blind, placebo-controlled study, researchers determined if omalizumab administration would be associated with attenuation of aspirin-provoked bronchospasm in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization. Sixteen-week omalizumab administration in atopic AERD subjects was found to be related to “clinically silent” desensitization. Relative to those randomized to placebo, an overall difference in urinary LTE4 (urinary leukotriene E4) levels was seen in subjects who received omalizumab and did not have respiratory reaction during desensitization. Significantly higher urinary LTE4 levels were detected with respiratory reaction in placebo subjects, relative to the levels detected after the 100 mg dose in AERD subjects who had no respiratory reaction.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries